Drug Reactions and InteractionsCytochrome P450 Enzymes (Table 7-11) - Major drug-metabolizing enzymes that are most predominant in the liver but can also be found in other organs (i.e., intestine, lung)
- Drug interaction involving p450 enzymes typically occur from one of two processes: enzyme inhibition or enzyme induction
- Enzyme inhibition: competition with another drug for the enzyme-binding site
- Enzyme induction: drug stimulates synthesis of more enzyme protein, enhancing metabolizing capacity of the enzyme
- Different isoforms: CYP2D6, CYP3A4 (most abundant cytochrome enzymes in humans and involved in many clinically important drug interactions), CYP1A2, CYP2C9, CYP2E1, CYP2C19
- Many drugs are substrates (metabolized by specific p450 isoenzyme) but unable to inhibit or induce the p450 enzymes
| | | | Table 7-11 Cytochrome p450 Drugs | | Cytochrome p450 Substrates | | 3A4 Inducers | | 3A4 Inhibitors | | Anti-arrhythmics Digoxin Quinidine Amiodarone
Antibiotics Erythromycin Clarithromycin Rifampin
Anticonvulsants Phenytoin Carbamazepine Ethosuximide
Antidepressants Amitryptaline Doxepin Sertraline Imipramine
Antihistamines Fexofenadine Terfenadine Astemizole | | Calcium Channel Blocker (CCB) Nifedipine Diltiazem Verapamil Felodipine
Immunosuppressants Tacrolimus Cyclosporine Dapsone Cyclophosphamide
Protease Inhibitors Indinavir Ritonavir Saquinavir
Statins Atorvastatin Lovastatin Simvastatin
Miscellaneous Glyburide Pimozide Theophylline Warfarin | | Anticonvulsants Phenytoin Phenobarbital Carbamazepine
Anti-TB drugs Isoniazid Rifampin
HIV antivirals Ritonavir
Miscellaneous Propranolol St. John’s Wort Omeprazole Griseofulvin | | Antidepressants Fluoxetine Paroxetine Sertraline
Azole Antifungals Ketoconazole Itraconazole Fluconazole
Antibiotics Erythromycin Clarithromycin Ciprofloxacin Metronidazole
CCBs Verapamil Nifedipine Diltiazem
Miscellaneous Cimetidine Cyclosporine Quinine Grapefruit Juice Warfarin
Protease Inhibitors Ritonavir | | Warfarin + phenobarbital/rifampin/phenytoin → decreased levels of warfarin | | Warfarin + cimetidine/erythromycin/itraconazole/ketoconazole → increased levels of warfarin | | Cyclosporine + itraconazole → increased levels of cyclosporine | | | | | | | | |
| | | | |
|
| | | | Table 7-12 Drug Reactions | | Reaction | | Culprit drugs | | Acneiform lesions | | Corticosteroids, androgenic steroids, phenytoin, INH, lithium, halogens, (bromides, iodides), epidermal growth factor receptor inhibitors (EGFRI) such as erlotinib, cetuximab, gefitinib | | Acral erythema (erythrodysesthesia) | | Doxorubicin, daunorubicin, 5-fluorouracil, cytarabine, docetaxel, methotrexate (MTX) | | Acral sclerosis | | Bleomycin | | AGEP (acute generalized exanthematous pustulosis) | | β-lactam antibiotics, macrolides, calcium channel blockers (i.e., diltiazem), chloroquine, terbinafine | | Alopecia | | Alkylating agents (i.e., cyclophosphamide), anthracyclines (doxorubicin, daunarubicin), taxanes (paclitaxel, docetaxel), vincristine, vinblastine, actinomycin-D, etoposide | | Autoimmune hepatitis | | Minocycline (MCN) | | Bullous pemphigoid | | Furosemide, PCN, captopril, β-blockers, sulfonamides, terbinafine, penicillamine | | Dermatomyositis-like eruption | | Hydroxyurea, penicillamine, statins | | Eccrine squamous syringometaplasia | | Cytarabine, cyclosphosphamide, paclitaxel, docetaxel, busulfan, carmustine | | Elastosis perforans serpiginosa (EPS) | | D-penicillamine | | Erythema nodosum | | OCPs, antibiotics (sulfonamides, tetracyclines), NSAIDs | | Extravasation reaction (ulcer, chemical cellulitis) | | Anthracyclines (doxorubicin/daunorubicin), actinomycin-D, docetaxel, paclitaxel, vinblastine, vincristine, etoposide, 5-fluorouracil (5-FU) | | Fixed drug eruption (FDE) | | NSAIDS (naproxen), sulfonamides, TCNs, acetaminophen, aspirin, OCP, phenolphthalein, pseudoephedrine (non-pigmenting variant), barbiturates | | Flag sign (of chemo) | | MTX (horizontal hyperpigmented bands of hair alternating w/ normal color) | | Gingival hyperplasia | | Phenytoin, cyclosporine, CCBs (i.e., nifedipine, amlodipine) | | Hyperpigmentation | | Antimalarials, clofazamine (violet-brown to blue in lesional skin), imipramine, amiodarone (blue-gray), phenothiazines (chlorpromazine, promethazine, prochlorperazine), chemotherapeutics (busulfan, cyclophosphamide, hydroxyurea, dactinomycin, MTX, 5-FU), and minocycline (see below): | | | Type 1: blue-black color within scars, + iron (hemosiderin) with Perls stain {MCN pigmentation} | | | Type 2: blue-gray color on shins, + melanin (Fontana-Masson stain), + iron (Perls stain) {MCN pigmentation} | | | Type 3: generalized “muddy brown” hyperpigmentation in sun-exposed sites (↑ melanin within epidermis, no iron deposition) | | Hypersensitivity syndrome | | Aromatic anticonvulsants (phenytoin, phenobarbital, carbamazepine, lamotrigine, oxcarbazepine), sulfonamides, allopurinol, dapsone, gold, olanzapine, saquinavir | | Hypertrichosis | | Cyclosporine, phenytoin, minoxidil, danazol, anabolic steroids | | Inflamed AKs | | 5-fluorouracil, capecitabine, pentostatin | | Inflamed SCC | | Fludarabine | | Inflamed SKs | | Cytarabine, docetaxel | | Leg ulcers | | Hydroxyurea | | Leukocytoclastic vasculitis | | Antibiotics (especially β-lactam antibiotics), NSAIDs, diuretics | | Lichenoid eruption | | Penicillamine, gold, hydrochlorothiazide (HCTZ), furosemide, β-blockers (propanolol, labetalol), ACEI (captopril, enalapril), chlorpromazine, antimalarials (chloroquine, hydroxychloroquine, quinacrine), quinidine | | Linear IgA bullous dermatosis (LABD) | | Vancomycin, β-lactam antibiotics, NSAIDs, captopril, phenytoin, sulfonamides, furosemide, amiodarone, lithium | | Localized hyperpigmentation | | Flagellate hyperpigmentation: bleomycin | | | Supravenous serpentine hyperpigmentation: 5-FU | | | Sun-exposed hyperpigmentation: daunorubicin, 5-FU, MTX | | | Mucosal: busulfan, cyclophosphamide, 5-FU, hydroxyurea, doxorubicin | | | Occluded areas: thiotepa, ifosfamide, topical carmustine, docetaxel, cisplatin | | Lupus | | SCLE: HCTZ, griseofulvin, terbinafine, CCBs | | | SLE: hydralazine, procainamide, isoniazid, MCN, phenytoin, penicillamine | | Melanonychia | | Chemotherapeutics (melphalan, hydroxyurea, bleomycin, capecitabine, doxorubicin), lamuvidine, MCN, zidovudine (AZT) | | Mucositis | | Cyclophosphamide, daunorubicin, doxorubicin, MTX (high dose), 5-FU | | Neutrophilic eccrine hidradenitis | | Doxorubicin, daunorubicin, cytarabine, 5-FU, MTX, bleomycin, cyclosphosphamide, busulfan, taxanes | | Onycholysis | | Paclitaxel, docetaxel, etoposide, retinoids, doxorubicin, captopril | | | Photo-onycholysis: TCN, OCPs, fluoroquinolones, psoralens | | Orange-red body fluid | | Rifampin | | Pemphigus vulgaris | | Thiol drugs (penicillamine, captopril, lisinopril, piroxicam, gold sodium thiomalate), penicillins, cephalosporines, quinolones, rifampicin, phenylbutazone, propranolol, carbamazepine | | Penile ulcers | | Foscarnet | | Photosensitivity (includes allergic and toxic reactions) | | Griseofulvin, NSAIDs, phenothiazines, sulfonamides, thiazides, dapsone, MTX, hydroxyurea, 5-FU, fluoroquinolones, TCNs, furosemide, diltiazem, isotretinoin, imipramine, chlorpromazine, phenothiazines | | Pseudoporphyria | | NSAIDs (naproxen, piroxicam), nalidixic acid, furosemide, HCTZ, isotretinoin, TCNs, sulfonamides | | Pseudotumor cerebri | | TCN, isotretinoin | | Pseudoxanthoma elasticum (PXE) | | Penicillamine | | Psoriasis (induce/worsen) | | Terbinafine, NSAIDs, antimalarials, ACEI, lithium, β-blockers | | Pulmonary fibrosis | | MTX, bleomycin, busulfan, amiodarone, gold, penicillamine | | Radiation recall | | Doxorubicin, daunorubicin, paclitaxel, docetaxel, MTX, actinomycin-D, capecitabine, gemcitabine, bleomycin | | Raynaud’s phenomenon | | Combination of bleomycin and vinblastine | | Sweet’s syndrome | | Granulocyte colony-stimulating factor (GCSF), carbamazepine, trimethoprim-sulfamethoxazole (TMP-SMZ) | | Toxic epidermal necrolysis (TEN) | | Allopurinol, PCNs, anticonvulsants (carbamazepine, lamotrigine, phenytoin), sulfonamides, antiretrovirals, barbiturates, NSAIDs | | | | |
| | | | |
|
|